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ABSTRACT 
Background. Artemether-lumefantrine (AL) is widely adopted as first-line treatment for 
uncomplicated malaria. Lumefantrine (LUM), the long acting partner drug is critical for 
cure by eliminating malaria parasites left after artemether exposure. Absorption of LUM is 
dependent on dietary  fat and the basis for the pediatric dose recommendations is unclear.  
Aim. To explore effect of local foods on oral bioavailability of LUM and describe its 
population pharmacokinetics (PPK) among under five year old children in Uganda treated 
for malaria with the aim of optimizing use and provide basis for AL rational dosage 
guidelines.  
Methods. In an intensive pharmacokinetics (PK) study, 13 healthy adult volunteers were 
randomized to participate in an open-label four period crossover design and received a 
single oral dose of AL (80mg A/ 480mg of LUM) with water, milk, maize porridge or 
maize porridge with oil on separate occasions. Peak concentrations (Cmax) and area under 
concentration-time curve (AUC) truncated at 48 hours after a single dose (AUC0-48h) were 
compared using average bioequivalence techniques (I).  Relevance of the findings was 
assessed among children < 5 years with uncomplicated falciparum malaria who were 
randomized in a parallel study design to receive standard weight-based AL treatment 
(Coartem
®
), 6 doses over 3 days, with either milk or maize porridge with oil (n= 33) (III). 
Parametric two-sample t-test was used to compare relative oral LUM bioavailability, 0 to 8 
h after the first dose (AUC0-8h) (III). This bioavailability study (III) was nested in a 
population pharmacokinetic (PPK) study (IV) in the same pediatric patient group. After 
treatment, sparse plasma samples were collected during 28 days’ follow up in all children 
(n=55). NONMEM was used to describe the PPK profile of LUM and its metabolite, 
desbutyl-lumefantrine (DBL) (IV).  
A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed 
for determination of low concentrations of LUM and DBL in small amounts of plasma (II).  
Results.  
The LC-MS/MS method was simple, fast and sensitive requiring only 100 μl of plasma 
with limits of quantification of 21 and 1.7 ng/ml for LUM and DBL respectively (II). 
Lumefantrine exposure was comparable in milk and maize porridge plus oil study groups 
(I & III). In adult healthy volunteers, the bioequivalence criteria was met [maize porridge 
plus oil group ranges for means ratios (90% CI) of 0.84 –1.88 and 0.85 – 1.69 for Cmax 
and AUC0-48h respectively, relative to milk (90%CI, 0.80 – 1.25)]. Among pediatric 
patients, LUM (AUC0-8h) for those dosed with milk (n=16) was comparable to maize 
porridge plus oil (n=17) arm (GM {95%CI}: 6.01 {3.26-11.1} vs 6.26 {4.5 -8.43} 
h*μg/ml, p=0.9).  
A two-compartment PK model with lag time using first order processes characterized the 
PPK of LUM (IV). Inter-subject variability in apparent oral clearance (CL/F) was 
explained by body mass index (BMI) and age, while that in apparent volume of 
distribution of the central compartment (VC/F) was explained by weight. Lumefantrine 
population mean CL/F, inter-compartment clearance (Q/F), VC/F and apparent volume of 
distribution of peripheral compartment (VP/F) were 3.19 L/hr, 0.176 L/hr, 28.1 L, and 
58.4 L, respectively. Our results indicate that LUM CL/F decreased with age from two to 
just less than five years (≈20.6%. p=0.04) and LUM CL/F increased with decreasing 
BMI. 
Conclusions. The LC MS/MS method is suitable for pediatric studies with repeated 
sampling and long time follow up. Oil fortified maize porridge can be an alternative to milk 
in augmenting absorption of LUM. Our findings provide a structural basis for consideration 
of age and BMI in evaluation of rational AL dosing guidelines among under five year old 
children.  
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OPERATIONAL DEFINITIONS  
Bioavailability: the amount or fraction (measured by both rate and extent) of the 
administered dose of unchanged form of therapeutically active agent that reaches the 
systemic circulation and is available at the site of action [127, 190]. 
Absolute bioavailability: the amount of a therapeutically active agent that reaches the 
systemic circulation relative to that given by the intravenous route. Ideally the 
intravenous dose is assumed to be 100% available [190]. 
Oral bioavailability: rate and extent of absorption of an orally administered 
therapeutically active agent that reaches the systemic circulation and is available at the 
site of action. [190]. 
Relative bioavailability: estimate of the fraction of a dose administered through another 
route that is absorbed into the systemic circulation when compared to the fraction 
available when given as an intravenous dose form, or comparisons between fractions 
absorbed when a drug is administered in 2 different forms (different route of 
administration or formulation- solution, suspension or same form but different product 
/brands) or when given with different supplements [190]. 
Bioequivalence: the absence of a significant difference in bioavailability of therapeutic 
equivalents or alternatives at the site of drug action or in systemic circulation when 
administered at the same molar dose under similar conditions [190]. 
Pharmacokinetics: the way the body handles the therapeutic agent after it has been 
administered; once the therapeutic agent has been released it undergoes subsequent 
processes including absorption, distribution, metabolism and excretion [192]. 
Population pharmacokinetics: the study of variability in plasma drug concentrations in 
patient population when standard dose regimens are administered [127]. 
Apparent oral clearance (CL/F): the volume of plasma cleared of the therapeutic agent 
(which has been administered orally) per unit of time [133]. 
Apparent volume of distribution (VC/F): “the theoretical volume that would be 
necessary to contain the total amount of an administered drug at the same concentration” as 
that being observed in the blood plasma [133].
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1 INTRODUCTION 
Malaria remains one of the leading causes of death among children below the age of 5 
years living in sub-Saharan Africa (SSA) [1]. Uncomplicated Plasmodium falciparum 
malaria accounts for above 95% of clinical attacks and if not well treated, rapidly 
progresses to severe disease among children < 5 years of age [2]. Effective case 
management is still the cornerstone in malaria control.  Artemisinin based combination 
therapies [ACTs] are recommended to optimize treatment response and reduce the risk of 
development of drug-resistant parasites [3]. Artemether-lumefantrine [AL] was selected as 
first-line ACT for uncomplicated falciparum malaria in Uganda in 2004 and is a widely 
adopted policy in SSA countries [3-5].  
Lumefantrine (LUM) is the long acting antimalarial partner agent responsible for ensuring 
cure [3]. In SSA including Uganda, global financial initiatives [6, 7] through World Health 
Organization (WHO) and governments’ commitment have scaled up availability of ACT at 
public health facilities for treatment of childhood diseases at community level [8-12]. 
However oral bioavailability of LUM is highly dependent on intake of dietary fat and the 
basis for the AL dosage regimen among children is still unclear.  
This thesis sought to optimize use of AL during treatment of uncomplicated malaria, to 
benefit the most vulnerable users and provide a pharmacokinetic basis for evaluation of 
rational AL dosage guidelines for children under five years of age.  
1.1 MALARIA BURDEN 
Malaria is one of the commonest mosquito-borne diseases in humans [1]. The infection is 
caused by six Plasmodium species namely P. falciparum, P. malariae, P. vivax, two 
species of P. ovale (classic type P.ovale curtisi and variant type Plasmodium ovale 
wallikeri) [13, 14] and P knowlesi [15].  P. falciparum species is the commonest infection, 
responsible for the highest disease burden and fatality [1, 2].  
Globally, 3.3 billion people are estimated to be at risk of malaria, with disproportionately 
high risk among those with poorly developed immunity and living in tropical climate 
especially in resource limited settings in SSA [1]. In 2015, WHO estimated “214 million 
cases of malaria globally, 88% of which occurred in Africa” and “438, 000 deaths, 90% of 
which occurred in Africa” and children < 5 years accounted for about 70 % of all deaths 
[1]. In 2015, Uganda was ranked 4
th 
highest malaria burdened country in Africa and 10
th
 
global contributor to malaria related mortality [1]. Though mortality among children aged < 
5 years reduced by 34% from 137 to 90 /1,000 live births between 2004 and 2011 [16]. 
Malaria remains one of the leading causes of illness and death for this age group in Uganda 
[17]. Available data in 2013 by the Uganda ministry of health (MoH) estimated 16 million 
malaria cases to have contributed to 30%-50% of all outpatient visits, 15%-20% of hospital 
admissions and 12.8% hospital deaths [17, 18]. Surveys conducted among Ugandan 
children < 5 years of age, registered reduction in malaria prevalence by microscopy from 
42 (range: 5 – 63) % in 2009 [19] to 19 (range: 6-22) % in 2014 [20]. Of note, malaria was 
reported to be “four times more prevalent in rural than in urban areas” and “seven times as 
common among children in the lowest compared to those in highest wealth quintile” [20]. 
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Thus the need to optimize AL use in resource limited settings where malaria is most 
prevalent.  
1.2 HISTORY AND TREATMENT OF UNCOMPLICATED MALARIA   
For long, treatment of uncomplicated falciparum malaria was effective with monotherapy 
using 4-aminoquinolines such as chloroquine (CQ), amodiaquine (AQ) or co-formulated 
antifolate drugs such as sulphadoxine -pyrimethamine (SP). Parasite resistance to CQ was 
reported in 1950s in South America [21], later in 1960s in East Asia [22] and reported to 
have increased between 1973 and1981 in Southeast (SE) Asia and South America [23-25]. 
Worldwide, malaria transmission heightened between 1982 and 1995 [26]. Resistance to 
CQ was first reported in East Africa (Kenya & Tanzania) in 1978 [27, 28] but documented 
much later in Uganda in 1988 [29, 30]. Uganda MoH provisionally adopted CQ+SP in 
2000 but confirmed the combination as first line treatment of uncomplicated falciparum 
malaria, later in 2002 [30]. In Uganda, CQ monotherapy for P. falciparum continued 
beyond 2002 and remained efficacious in a few low transmission areas [31].  However 
increased treatment failure rates were reported especially in children < 5 years [32, 33]. 
Though resistance to SP had been reported as early as 1985 [34, 35], SP was effective 
when used in combination with 4-aminoquinolines [36-38]. Nevertheless use of CQ + SP 
was short-lived with increasing treatment failure [37-45]. In 2004, Uganda adopted AL as 
first line treatment of uncomplicated malaria but was not used widely until 2005 [4].  
The WHO recommends ACT regimens. Short acting artemisinins are combined with long 
acting partner drugs to optimize cure rates, reduce the risk of development of resistant 
P.falciparum and reduce malaria transmission [46-48]. Current treatment options for 
uncomplicated falciparum malaria (except pregnant women in first trimester) include AL, 
AQ and artesunate (AS), AS + mefloquine, AS + SP, and dihydroartemisinin plus 
piperaquine [3, 49]. For pregnant women in first trimester, quinine plus clindamycin is 
recommended [3]. 
1.3. CLINICAL TRIALS OF ARTEMETHER-LUMEFANTRINE IN AFRICAN 
CHILDREN  
The current standard AL regimen with 6 doses at 0, 8, 24, 36, 48, 60 hours has been 
efficacious with day 28 cure rates among African children in clinical trials ranging between 
95 and 100% [50-59]. However, a recent meta-analysis indicated low cure rates among 
Asian children between 10 and 15 kg; and malnourished African children between 1- 3 
years [60]. Efficacy may be lower in real life situations. Indeed effectiveness studies in 
African children have reported varying trends, ranging from those observed in clinical trials 
to higher failure rates (4%-39%) [61-64]. In Africa, trials comparing AL with another 
commonly used ACT, dihydroartemisinin plus piperaquine (DP) showed lower Day 28 
PCR adjusted parasitological failure rates with DP {range 2-5.8 %  vs 0- 2.0% for AL vs 
DP respectively} [65-70]. This may be explained by better absorption and longer half-life 
of the long acting partner drug piperaquine compared to LUM.  
 
 
  3 
1.4 RELATIONSHIP BETWEEN LUMEFANTRINE EXPOSURE AND 
MALARIA TREATMENT OUTCOME 
The risk of therapeutic failure during AL treatment is attributed to low PK exposure of the 
long acting partner LUM [71-73]. Predictors of therapeutic response have been identified 
as the overall area under LUM plasma concentration- time curve (AUC) and increased time 
during which LUM concentrations were above minimum inhibitory concentration of 280 
ng/ml [72]. Venous plasma LUM concentration on day 7 (C(LUM)D7) has been found to be a 
surrogate marker of the overall AUC [72, 74, 75]. Various C(LUM)D7 ranging from 50, 175, 
400, 500, 600 ng/ml, have been correlated with therapeutic response in different clinical 
studies [72, 76-79]. The two most commonly referenced C(LUM)D7 as prediction threshold 
for recrudescence have been  280ng/ml, first described among Thailand patients in an area 
of highly drug resistant P. falciparum [72]  and 175 ng/ml among Thailand patients in low 
malaria transmission area [76]. In another study in Uganda, C(LUM)D7 < 280 ng/ml did not 
predict treatment failure, but re-infections were registered in patients with  C(LUM)D7  < 400 
ng/ml [79, 80]. In this Ugandan population, predictors of low C(LUM)D7 and increased risk 
of malaria re-infection were reported to be age below 5 years and a low total LUM dose 
between 50 and 79 mg/kg [79]. In a real life study in Tanzanian children, significant 
correlation between low LUM exposures and increased risk of treatment failure was 
demonstrated [63]. The WHO recommends “target total dose ranges” of “5- 24 mg/kg of 
artemether” and “29-144 mg/kg of LUM” to provide adequate drug exposure [3].  
1.5 HISTORY AND PHARMACOLOGY OF ARTEMETHER-
LUMEFANTRINE  
Artemether (A) is co-formulated with LUM in fixed ratios of 1:6 {20mg of A and 120 mg 
of LUM} administered as weight-based fixed-dose: 5 to < 15 kg receives 1 tablet {20 mg A 
/120 mg LUM}, 15 to < 25 kg receives 2 tablet {40mg A/240 mgLUM}, 25 to < 35kg {60 
mg A / 360 mg LUM}, and ≥ 35 kg {80 mgA/480mg LUM}[81].  
Development of AL combination was started in 1981 by Zhou Yiqing and colleagues at  
Academy of Military Medical Sciences, Beijing, China (www.epo.org/learning-
events/european-inventor /finalists /2009/ zhou.html). Artemether lumefantrine was the 
first co-formulated ACT and was approved for use in China in 1992 [82]; in 1999 in Africa 
and the European Union and as late as 2009 by the US Food and Drug Administration [83].  
The dispersible formulation for use in children was availed in 2009 [83]. Artemether-
lumefantrine is effective against all malaria species although it is particularly indicated for 
treatment of uncomplicated P. falciparum and P. vivax [3]. 
1.5.1  History, pharmacokinetics and pharmacodynamics of artemether 
Artemether (A), {C16H26O5, molecular weight [mw] 298.38 Da} is a lipid-soluble semi-
synthetic artemisinin derivative from  Artemesia annua,  a traditional Chinese medicinal 
plant.  The active component of artemisinins {qinghaosu} was first extracted and 
chemically isolated in 1971 by Youyou Tu [84-86] and  evaluated for clinical use in 
1981[87,88]. Youyou Tu received the 2015 Nobel Prize in Physiology / Medicine.  
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Artemether is currently given orally or intramuscularly. Oral absorption of A is enhanced 
by fatty food and is rapid with lag time between 0.13 and 2 h and peaks within 1-2 h [74, 
89-91].  Artemether {t1/2 =1-3 h} is metabolized predominantly by CYP 3A4 and to minor 
extent by CYP2B6, 2C9, and 2C19 [81, 92]. Artemether is more rapidly eliminated than its 
active metabolite dihydroartemisinin {t1/2 =1 – 5 h} [74, 93, 94] and undergoes auto 
induction (enzymatic metabolism) with subsequent doses [95]. Artemisinins are 
sesquiterpene lactone endoperoxides that exert rapid parasite clearance. Direct reduction of 
their endoperoxide ring by iron in heme generates reactive oxygen radicals which rapidly 
kill most stages of blood ring forms, trophozoites and schizonts of all Plasmodium species 
[96, 97]. Artemisinins also affect activities of parasite mitochondria, inhibit nucleic acid 
and protein synthesis [98, 99]. Other pharmacodynamic (PD) effects of A include inhibition 
of adhesions process (cytoadhesion and resetting) associated with severe form of P. 
falciparum malaria [100]. Resistance to arteminisins (K13 gene mutation) has been 
reported in SE Asia [101-102]. Similar mutations were found in East and West Africa but 
these isolates were not validated to confirm association with clinical resistance [103-105].  
1.5.2 History and pharmacodynamics of lumefantrine 
Lumefantrine is the long acting schizonticidal agent in the AL combination, responsible for 
eliminating the residual parasites surviving short acting A exposure [73]. Lumefantrine 
(benflumetol {C30H32Cl3NO, mw 528.95 g/mol}, 2-dibutylamino-dichlorobenzylidene-H-
fluorenyl-ethanol) is a synthetic aryl amino alcohol.  It was synthesized by 1976 under 
Academy of Military Medical Sciences in Beijing, China and certified for manufacture in 
1989 by Kunming Pharmaceutical Company [82, 106]. Lumefantrine has schizontocidal 
effect on erythrocytic stages of all Plasmodia species and also gametocidal activity [3, 
107]. The mechanism of action of LUM is not clearly defined but it is thought to be similar 
to that of quinolines and related aryl alcohols [108]. The drug accumulates in the parasite 
food vacuole and interferes with heme polymerization by forming complexes. Thus inhibit 
formation of non-toxic hemozoin. Accumulated toxic heme leads to parasite death and also 
inhibits parasite nucleic acid and protein synthesis [108].  Although molecular markers 
associated with LUM resistance (P. falciparum multidrug resistance genes, pfmdr-1 86N, 
184F, and 1246D alleles) have been found in African clinical samples where AL has been 
widely used, this has not yet been associated with clinical failure [109- 111]. 
1.6 PHARMACOKINETICS OF LUMEFANTRINE 
Lumefantrine is currently only available as an oral co-formulation with A for human use.  
However PK comparison of parenteral and oral LUM in rats indicated poor erratic oral 
absorption with absolute oral bioavailability ranging between ≈ 5 and 12%; and a low 
extraction with clearance of 0.03 liters/h/kg (< 2% of the hepatic plasma flow) [112]. 
Lumefantrine is highly lipid soluble with slow and erratic fat dependent absorption [91] 
with lag time of 2-4 h and peaks between 4 and 10 hr after an oral dose [72, 91, 113]. 
Lumefantrine binds variably to plasma lipoproteins (77%, 7.3%, 6.6% for high, low and 
very low density lipoproteins respectively) and minimally (10%) to erythrocytes [114]. 
Estimates of apparent oral clearance (CL/F) (range 0.077-0.104 L/h/kg) and apparent 
volume of distribution (V/F) (range: 0.4-8.9 L/kg) of LUM have been summarized by 
WHO [3]. The half life (t1/2) of LUM is variable, ranging from 3 to 10 days among healthy 
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adult volunteers [113, 115, 116] and malaria patients including children and pregnant 
women [72, 117, 118]. Some studies reported significantly shorter LUM t1/2 (range 1- 4 
days) in pediatric patients [119, 120] and among pregnant women compared to non-
pregnant adults [121,122].  Lumefantrine undergoes predominantly hepatic excretion, and 
both parent and metabolites have been found in bile and faeces during animal studies [115]. 
There is no published data on the extent of renal excretion of LUM. 
Lumefantrine is metabolized mainly to desbutyl-lumefantrine {DBL} predominantly by the 
liver microsome enzyme CYP3A4 [81, 113]. The metabolite has anti-malarial activity 
[123-124] but systemic exposure of DBL is low ranging between 0.8% and 14 % of that of 
the parent drug [76, 81, 117, 125, 126]. The half life (t1/2) of DBL was reported to be 
slightly longer than that of the parent drug in one study among children {median 5.3 vs 5.9 
days} [117].  
1.6.1 Factors influencing lumefantrine exposure  
Drug exposure is a result of various PK processes including absorption, distribution, 
metabolism and excretion [127]. Differences in LUM PK exposure are mostly attributed 
to absorption (section 1.6.1.1) and metabolism (section 1.6.1.2). Variation in LUM 
exposure can also be caused by physiological changes including pregnancy [118, 
121,122] and pharmacogenetic variations in CYP3A4 enzymes [128].Variation in 
CYP3A4 activity as a result of physiological maturation changes has been reported to 
affect exposure of some substrates (section 1.6.2).  
1.6.1.1 Effects of food on lumefantrine absorption  
Oral bioavailability of LUM is highly variable but dependent on food intake [91, 129, 130]. 
This was evident in malaria patients as they resumed normal diet [72, 74]. Among healthy 
volunteers, high fat meals augmented oral bioavailability of LUM as much as 16-fold 
compared to only two fold increase for A [91, 129]. At least 1.2g of fat is needed to 
sufficiently improve LUM absorption [130].   
The clinical importance of dietary fat was demonstrated in an earlier study, day 28 PCR 
adjusted cure rates varied significantly between patients who received AL with food and 
those dosed without food (86.5% vs. 71.1%, p=0.02) [78]. No significant difference in 
clinical outcomes was observed in studies examining unsupervised and supervised AL 
therapy in three different countries [64, 77, 79]. However, in two of these studies, 
significantly lower C(LUM)D7  were observed with unsupervised AL treatment compared to 
the supervised groups  [64, 77].  
Concern still remains whether optimal LUM levels are attainable in real life situations 
when unsupervised outpatient AL treatment is inevitable and in areas where milk may not 
be easily available. A study conducted in 5 African countries reports that only 57.5% of the 
AL doses were administered with milk [131]. In Tanzania, only 43% of hospitalized 
pediatric patients receiving AL for treatment of uncomplicated falciparum malaria were 
able to complete their milk portions [120]. Thus, smaller meals but with sufficient fat 
content may be necessary.   
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1.6.1.1.1 Factors affecting bioavailability of orally administered drugs 
Oral bioavailability of a drug depends on both pharmaceutical (properties, bioequivalence, 
drug interactions) [132] and patient factors (physiological processes and co-morbidity) 
[133]. Drug-related factors involved are physicochemical properties of the drug (solubility, 
size, lipid solubility, stability) and the formulation (design and form) [132, 134]. Patient 
related factors include gastrointestinal {GIT} physiological processes and food effect on 
absorption [132, 135, 137, 138]. These include alterations in P
H
 of GIT contents and 
hepatic blood flow [132]; drug efflux by ATP-binding cassette (ABC) transporters p-
glycoprotein and metabolism at the intestinal mucosa [139, 140]. Gastric emptying varies 
with dietary content, mechanical effects such as volume and state of food, either solid or 
liquid and food viscosity [133, 135, 136].  
Mechanisms responsible for poor LUM oral bioavailability are attributed to its 
physicochemical properties and GIT barriers to absorption [139].  The solubility of LUM 
and availability for absorption is enhanced by dietary fat [91, 129, 130]. Fat delays gastric 
emptying which prolongs bile secretion necessary for emulsification of fat thus augments 
absorption of lipid soluble drugs like LUM [133, 135]. Absorption of LUM is further 
moderated by enterocyte CYP3A4 metabolism and efflux activity by ABC transporters at 
intestinal epithelial cell level [139].    
1.6.1.1.2 Assessment of bioavailability  
Oral bioavailability is a measure of drug exposure, estimated by the rate and extent to 
which an orally absorbed drug reaches the systemic circulation or site of action [127]. 
Assessment of bioavailability employs direct PK outcomes (estimates of drug levels in 
circulatory or excretory compartments) and rarely indirect PD outcomes (immediate 
pharmacological or therapeutic responses) [141]. Pharmacokinetic measures include the 
rate of exposure {time of onset of absorption (Tlag) and to peak (Tmax)} and extent of 
exposure {peak concentration (Cmax), in respect to concentrations attained over time 
(AUC)} of exposure [141].  
Bioequivalence (BE) assumes the absence of significant difference in the bioavailability 
and therefore similar therapeutic and safety effects of innovator drug and therapeutic 
equivalents (generic drug products) or alternatives (different formulations) [141]. Average 
bioequivalence {ABE} technique compares PK outcome measures of reference and test 
drug/pharmaceutical products. The two are bioequivalent if the confidence interval 
{90%CI} for the ratio of means of the drug exposure is within bioequivalence limits (0.80-
1.25) [141]. However it may be argued that bioequivalence may not deem that the products 
can be used interchangeably, some drugs are highly variable [142] and drug products may 
display significant differences in variance in PK estimates due to inter-individual and intra-
individual variability [143-146]. So, other BE criteria may be considered [143-146].  
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1.6.1.2 Drug-drug interactions influencing lumefantrine exposure 
Drug- drug interactions influencing LUM metabolism has been reported.  Cytochrome 
P4503A4 inhibitors such as ketoconazole [120] and protease inhibitors {lopinavir, 
lopinavir/ ritonavir, darunavir/ritonavir} [127, 147-151] have been reported to increase 
LUM exposure when given concurrently.  Lumefantrine exposure was reduced when AL 
was co-administered with CYP3A4 inducer such as efavirenz [147, 149, 152-154], 
etravirine [151] and rifampicin [155]. Lumefantrine has been reported to inhibit CYP2D6 
[81]. 
1.6.2 Role of ontogeny on pharmacokinetics of drugs  
Ontogeny, the course of growth (size change) and development of an individual organism 
impacts on PK process [156]. Development entails physiological maturation which 
involves phenotypic (structural changes in size, shape and appearance) and functional 
changes in body systems including drug metabolizing enzyme systems [157 - 161]. 
Differences in PK between children ≥2 years of age and infants <2 years of age have been 
reported [156]. The maturation trends in CYP3A4 have been reported to reach peak at or 
after 6 months and appeared to decline after infancy or 2 years [162-164]. This trend has 
been observed for some CYP3A4 substrates including midazolam [165], tacrolimus [166] 
and lopinavir [167].  Lumefantrine is also a substrate for CYP3A4 [84, 120]. There is 
evidence pointing to lower LUM exposure  concentrations (C(LUM)D7) among children 
compared to adults treated according to the current dosage regimen [79, 80, 117, 119, 131, 
168, 169]. Therefore allometric scaling adjusted to physiological functional changes in 
relation to ontogeny of CYP3A4 with age can be incorporated into elimination PK models 
to help optimize parameter estimations [170].   
1.6.3 Challenges for pharmacokinetic studies among children  
Traditional PK methods employ intensive sampling designs. As such, studies often involve 
adult healthy volunteers and patients. These may not usually be valid for pediatric 
population with their developmental changes which are likely to alter physiological and PK 
processes [171]. Ethical considerations for not including children intensive PK studies 
involve avoiding inflicting pain, lack of certainty of consent and safety considerations of 
volume of blood to be drawn. This constrains research among young children and explains 
the lack of studies necessary for rational recommendation of pediatric dosage regimens.  
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1.7  POPULATION PHARMACOKINETICS 
1.7.1 Population pharmacokinetics methods    
Methodological limitations are associated with use of traditional PK analysis despite 
availability of dense individual data from few people. Population PK approach uses sparse 
data from larger populations to characterize population PK mean values, explain sources of 
variability in PK outcomes and relationships between PK and PD outcomes [172]. 
Population based PK methods describe both fixed effects (population mean estimates) and 
the contribution of the random effects [173]. Furthermore PPK models display the extent of 
variability. An individual estimate differs from the population mean by a value contributed 
by random effects from inter-subject differences and unknown influences. Unknown 
influences may include intra-subject differences, inter-occasion differences, measurement 
errors, and unexplained residual differences [173]. 
Population PK approaches commonly employ parametric methods (non-linear mixed effect 
modeling, NONMEM), first described by Sheiner and Beal in 1972 [174]. Non-linear 
mixed effect modeling assumes a population with approximate normal distribution of 
parameter estimates. However, non-parametric (NP) methods for population modeling are 
available {e.g. NP maximum likelihood, NP adaptive grid, NP Bayesian algorithm}, which 
make no assumptions about the parameter distribution. This makes NP methods suitable 
approach for characterizing population parameters for populations with uncertain or 
bimodal or multimodal distributions [175].  
1.7.2 Population pharmacokinetics of lumefantrine  
There is increasing data on PPK of LUM and its metabolite, DBL profiles. Studies have 
been done among children [117, 120, 177], children and adults [178], pregnant and non-
pregnant women [118, 179], and HIV populations on antiretroviral co-treatment (ART) 
[154, 180].   Population estimates for central compartment parameters (apparent oral 
clearance {CL/F} and volume of distribution {VC/F}) of LUM and DBL varied across 
similar and different populations (Table 1). Different structural PK models were used to 
characterize LUM and DBL population parameters (Table 1).  Furthermore, different 
approaches or assumptions were used to model DBL disposition. In some studies, the VC/F 
of DBL was fixed to that of parent drug, LUM [178, 179]; whereas others assumed 100% 
conversion of parent drug to metabolite [117, 180].  
The variability in CL/F was partially explained by dose, age and weight during an earlier 
dose finding trial among adult patients > 15 years [72]. In addition, the influence of the 
initial level of parasitemia on LUM bioavailability was also reported [72].  Another 
population PK study that enrolled children and adults with age ranging from 1 to 78 years 
(median: 9 years) identified body weight, age and height as significant covariates 
influencing CL/F [178]. They retained weight only in their model because weight 
correlated well with age and height. Their findings justified the current weight based LUM 
dosing approach [178]. Studies that involved pediatric malaria patients do not provide 
information particularly on the vulnerable, < 5 year old population [117, 120, 178]. These 
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studies in children did not identify any influential patient covariates. Lately, the PPK of 
LUM has been described in Ugandan children aged ≤ 2 years where age was found to have 
a positive influence on bioavailability [177].    
 
Table 1. Reported mean population pharmacokinetic estimates of lumefantrine and 
desbutyl-lumefantrine  parameters after six AL doses in children and adults.  
Study 
Ref 
 Study Population 
Location         Age
mr
  
Model 
(cpt) 
Tlag Ka   
(h
-1
) 
CL/F 
(L/h) 
  
V/F 
(L) 
Duration 
of 
sampling 
 (Number) (years) 
Children 
177 LUM 
 
Uganda 
(207)
#
 
1.2 (0.5 - 2) 2  - -  2.19 83.2 21 
days 
 117 
  
LUM Papua New 
Guinea (13) 
7.7( 5-10)  3  
 
- 0.461  7.29 
(a)
 
227 
(b)
 28 
days 
DBL   2   - - 701 
(a)
 51,100  
120  LUM  
 
Tanzania 
(n=50) 
4( 1-10)  
 
1  
 
1.92  
 
0.82  0.077
(d)
  8.9 
(b)
 3 
days 
Children , adults and pregnant women 
 178 LUM 
 
Tanzania 
(143) 
Pregnant 
(3/143) 
 9 (1-78 )   1  - 0.54 
 
7.7  265 7 
days 
 DBL  1  - - 4.8 - 
Pregnant and Non-pregnant women  
179 
 
LUM 
 
Tanzania. 
Pregnant 
(33) and 
Not (22) 
21 (18–41) 1  
 
- - 2.89 134 7 
days 
 
DBL 
 
1  
  
- 
 
2.6 
 
-  
118 LUM Uganda 
Pregnant 
(115) and 
Not (17) 
21 (15–38) 2  - (4.09)
(c)
 5.09 123   21 
days 
HIV Patients on Antiretroviral therapy with malaria co-treatment 
180 LUM Uganda 
(n=89) 
{LPV/r or 
EFV or 
NVP}  
36 (20-70)  
 
2  
 
- (6.27)
(c)
 4.77  68.9    3-5 
days 
DBL 1    489 22 800  
154 LUM  
 
Tanzania 
(194)  
{EFV or 
NVP}  
43 (21-67) 2   1.45  0.032  4.54  25.6     14 
days 
# : 107 children with  207 malaria episodes  cpt: Number compartment in disposition model. 
mr: median age (range). (a):unit, L/h/70kg . (b) Unit, L/70kg. (d):L/h/kg 
LPV, EFV & NVP: Lopinavir, efavirenz & niverapine based antiretroviral therapy (ART) 
All first order absorption except (c), mean transit time in hours for the transit absorption model. 
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1.8  CHALLENGES IN QUANTIFICATION OF LUMEFANTRINE IN BLOOD 
Lumefantrine determination is constrained by its physicochemical properties. Lumefantrine 
is heat labile therefore is easily degraded at room temperatures [181], and may not be stable 
for more than 6 months in -20°C [182]. This poses a challenge while sampling, during 
storage and handling of samples. Lumefantrine plasma levels may be potentially lowered 
during collection in field studies or during sample preparation in case samples are not 
immediately frozen and kept so until extraction.  Furthermore LUM is highly lipid soluble 
and bound to plasma lipoproteins [114]. Careful choice of solvents for sample extraction 
and mobile phase is required.  In preparation for a study among pediatric patients, capillary 
samples would be preferred to venous samples. Good correlation without significant 
variation between capillary and venous LUM concentrations was reported, but capillary 
levels tend to be slightly higher thus the need for a correction factor [183]. Venous plasma 
is therefore preferred for precise quantification of LUM concentrations. Furthermore, 
minimal but adequate volume of drawn blood is a crucial consideration when undertaking 
studies among young children. 
Recent establishment of anti-malarial activity of the metabolite, DBL underlines the 
importance for concurrent determination with the parent compound [123-125].  However, 
DBL is present in very low concentrations with a factor of up to 100x lower than the parent 
compound [76, 81, 117, 125, 126]. Therefore, HPLC-UV detection may not provide the 
required sensitivity for quantification of low concentrations of DBL [126].  
 Due to technical limitations including laboriously lengthy extraction process and low 
sensitivity, earlier high-performance liquid chromatography methods are not adequate for 
follow up of low LUM levels in small volume samples [126, 182, 184, 185]. Recently, 
more sensitive liquid chromatography tandem mass spectrometry techniques have been 
published [186-188]. The availability and use of isotope labeled internal standard is 
preferred in order to overcome matrix effect and ion saturation (interferences leading to 
signal suppression or enhancement) [188]. Thus, these isotopes are preferred as internal 
standards rather than structural analogues to LUM like halofantrine [187] in order to 
improve accuracy and precision of the quantification method [188].  
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1.9 RATIONALE FOR THIS STUDY  
Effective case management remains the cornerstone in malaria control. With exception of 
poorly developed host immunity to malaria and parasite resistance, low drug exposure is 
the other contributor to the increase of risk of malaria treatment failure [75].  
Artemether –lumefantrine is a widely adopted first-line ACT for uncomplicated malaria, in 
SSA including Uganda [3-5]. Furthermore, global financial support through WHO and 
government commitment has sustained prompt access to effective malaria treatment in 
SSA [6-10, 12]. However it is important to ensure optimal drug exposure during treatment.  
The long acting partner drug, LUM is responsible for adequate treatment outcomes by 
eliminating residual parasites, left after massive but short-lived clearance of parasites by the 
most potent short acting artemether [72, 113]. The critical role of food in augmenting 
artemether - lumefantrine uptake is well established [91, 129, 130]. Dietary fat is essential 
for augmentation of AL absorption particularly LUM which is highly lipid soluble [129]. 
Milk or high fat food is recommended food supplement for AL [81]. Milk is scarce and 
food consumption in most sub-Saharan countries is principally carbohydrate rich with little 
or poor fat content. It is not known whether adequately uptake of AL is achieved when 
given with available local foods with minimal fat content. However it has been confirmed 
that as little as 1.2g of fat sufficient improves LUM absorption [130]. This information can 
be used to identify appropriate alternative food supplements suitable for user populations.  
Children under five are especially vulnerable to malaria and are at higher risk of treatment 
failure than adults by virtue of their undeveloped immunity [1].  The basis for pediatric AL 
doses is still unclear [60, 169]. The dose is currently fixed-weight adjusted and probably 
based on adult data [3], yet maturation may impact on drug disposition [156-161]. Indeed 
meta-analysis findings indicated lower exposure among young and malnourished children 
compared to older children and adults treated under the current AL dosage regimen [60]. 
Scientific data on factors influencing variability in drug concentrations among vulnerable 
populations is necessary to lend credence to rational dosage guidelines [172]. There is 
sparse data on PPK of LUM among pediatric malaria patients but studies do not provide 
information particularly on the vulnerable, < 5 year old population [117, 120, 177, 178].   
For the intended bioavailability and PPK studies among pediatric patients with 
uncomplicated malaria, a sensitive analytical method was required. The method needed to 
be sensitive to allow determination of LUM and DBL concentrations in small plasma 
volumes obtained from young children during follow up to the study end point, which was 
28 days. 
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2 STUDY OBJECTIVES 
2.1  General objective 
To explore the effect of local foods on the pharmacokinetics of lumefantrine (LUM) and 
describe the population pharmacokinetics of LUM among Ugandan children; in order to 
optimize AL use and provide basis for suggesting rational dosage for artemether-
lumefantrine (AL) adjusted to the user population and conditions in the country.  
2.2       Specific objectives 
1. To determine the effects of local food (milk, maize porridge, maize porridge plus 
vegetable oil) on the bioavailability of LUM among healthy Ugandan adults after a 
single oral dose of co-formulated AL.  
 2.  To develop and evaluate a sensitive LC MS/MS method for determination LUM and 
its desbutyl-metabolite in small plasma volume. 
3.  To compare the effects of maize porridge plus vegetable oil versus milk on the oral 
bioavailability of LUM among under five year old Ugandan children receiving AL 
for uncomplicated falciparum malaria. 
4.  To describe the population pharmacokinetics of LUM among under five year old 
children in Uganda receiving AL for uncomplicated falciparum malaria. 
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3 METHODS  
3.1  STUDY SETTING  
The study was conducted at the Department of Pharmacology & Therapeutics, Makerere 
University College of Health Sciences, Kampala, Uganda. This is within the Mulago 
National Referral Hospital Complex Campus.  Drug assay was done at Department of 
Pharmacology & Therapeutics (I) and Division of Clinical Pharmacology, Karolinska 
University Hospital, Huddinge, Stockholm Sweden (II, III, IV).  
3.2  STUDY PARTICIPANTS  
3.2.1 Healthy Adult Volunteers (I) 
Healthy volunteers were respondent adult paramedical and nursing students attending 
Mulago Paramedical and Nursing Schools, Kampala, Uganda. The student population is 
largely of black origin, predominantly originating from Ugandan ethnic groups.  
3.2.2 Pediatric patients (II, IV) 
Pediatric patients were under five year old children suffering from uncomplicated  
P. falciparum malaria. Parents / guardians were approached at hospital outpatient 
departments of Mulago Hospital and surrounding public health facilities within 20 Km 
radius, including Kampala, Mukono, Wakiso and Mpigi districts (Central Uganda). Central 
Uganda is mesoendemic for malaria with low Entomological Infection Rates (EIR) of about 
8 [189].  
 
3.3  GENERAL METHODOLOGY  
This scientific work comprised of 4 experimental sub-studies. A bio-analytical method (II) 
was developed to facilitate drug assays for sub-studies III and IV. Food-drug interaction 
studies included an initial explorative bioavailability study in healthy adult volunteers (I) 
followed by a comparative bioavailability study (III) nested in the observational PK study 
among < 5 year old children treated for uncomplicated P. falciparum malaria (IV) (Figure 
1). Reference will be made to adult healthy volunteers as “adult volunteers” and < 5 year 
old sick children as “pediatric patients”.  
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Figure 1. A schematic diagram showing the study populations and designs for the 
pharmacokinetic studies. 
 
3.4 PROCEDURES FOR ADULT VOLUNTEERS BIOAVAILABILITY STUDY 
(I) 
3.4.1 Selection of adult volunteers 
The study was conducted between April and August 2009. Eligibility of consented healthy 
volunteers (n=13) was established based on history, clinical examination, hematological 
and chemistry laboratory parameters screening on days 21 to 2 prior to the study.   
3.4.2 Study design for the adult volunteers bioavailability study  
In open-label randomized study, adult volunteers were assigned to participate in a non-
replicate four period cross-over study design to explore effects of selected local foods on 
oral bioavailability of LUM after a single oral dose of AL.  
3.4.3 Data collection for the adult volunteer study  
Selection of food groups for the bioavailability study. Practical food alternatives were 
based on findings from a pilot survey (Mwebaza 2009, unpublished). Exit interviews were 
conducted with caregivers of malaria suffering children < 5 years, as they exited the health 
facility.  Maize flour was the commonest {100%} local food at Ugandan households 
{n=94} of caretakers of < 5 year old malaria sufferers, given a 3 days’ recall of food 
provided.  In Uganda, maize {25g flour constitute 500ml of porridge cost
˷
 $0.01} is 
cheaper and more available than milk {500 ml cost 
˷ 
$0.25}. However maize {0-4% fat: 0- 
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0.2g of fat / 100 ml of porridge} has much lower fat content than cow’s milk {3.4g of 
fat/100ml} (I). Maize can be cheaply fortified with little vegetable fat. Vegetable cooking 
oil is more affordable and available than milk, 20 ml of vegetable oil cost 
˷ 
$0.06.  
Profiled food groups were as follows: A: Fasted, received water {200ml}, B: Standard milk 
supplement {6.8g fat /200ml}, C: Maize porridge {0.5g fat / 200ml of porridge} D: Maize 
porridge fortified with vegetable oil {0.5g fat / 200 ml plus 5g/5ml of vegetable oil}. 
Data collection. Adult volunteers received a single oral adult treatment dose of AL 
treatment (Tablet Coartem
®
, Novartis Pharma AG, Basel, Switzerland, 4 tablets of 20 mg 
A/120 mg LUM) with assigned feed on separate occasions with a washout period of about 
4 weeks. They were instructed to fast ≥ 8hours prior to dosing and refrained from food for 
3 hours after dosing, but allowed water at liberty.  Intensive samples were collected over 
the first 72 hours, and thereafter weekly till day 28. Plasma was frozen at -38
0
C until 
analysis by modified HPLC-UV technique [126].  
3.4.4 Data management and analysis for the volunteer bioavailability study    
Though samples were available till day 28, PK evaluations were restricted to 48 hours. This 
was due to unfortunate freezer breakdown following 72 hours’ interruption in power 
supply. Half of the profiles had samples collected beyond 48 hours that thawed before 
analysis. Subsequently LUM stability was doubtful based on unsatisfactory reproducibility 
and repeatability of results. Consequently results for thawed samples were invalidated and 
assessment limited to last point, 48 h at which valid results were available for all individual 
profiles (I).   
Statistical and pharmacokinetic evaluations: Lumefantrine PK outcomes were determined 
using non-compartmental methods following single extra-vascular dose using WinNonlin 
Pro software [Phoenix version 6.2, Pharsight Corporation Inc., Mountain View, CA, USA]. 
These included time of onset of absorption (Tlag), peak concentrations in plasma (Cmax) and 
time to reach Cmax (Tmax) directly from observed data and partial area under concentration-
time curve from 0 to 48 hours (AUC0-48) calculated using linear trapezoidal interpolation. 
Appropriate parametric and non-parametric comparisons depending on the distribution of 
data {normal or not} were done for multiple followed by two group comparisons for both 
matched and unmatched data. The level of significance was set for multiple (p<0.05) and 
binary group comparisons (unadjusted p < 0.0083 across 4 groups).  
Relative oral bioavailability was assessed using the confidence interval approach for 
evaluation of average bioequivalence (ABE) for non-replicate cross-over studies adopted 
from standard guidelines [189]. Evaluations were based on log transformed estimates of 
normally distributed dependent variables namely Cmax and AUC0-48 (I).  
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3.5 PROCEDURES FOR PHARMACOKINETIC STUDIES IN PEDIATRIC 
PATIENTS (III, IV) 
3.5.1 Selection of pediatric patients 
Children aged between 6 months to 5 year old were eligible if they had microscopically 
confirmed uncomplicated P. falciparum malaria mono-infection as defined by WHO [3], 
(Paper III and IV) and parental/ guardians consent.  Exclusion criteria included  weight <5 
kg; severe / complicated malaria including hemoglobin < 5 mg/dl; mixed plasmodia 
infection; medication known to influence CYP3A4/5 enzymes; receipt of AL in the past 28 
days [3].  
3.5.2 POPULATION PHARMACOKINETIC (PPK) STUDY IN CHILDREN 
UNDER FIVE YEARS (IV) 
3.5.2.1 Population pharmacokinetics study design  
This was a prospective, non-comparative observational study. Children (6 months to < 5 
years) with uncomplicated falciparum malaria were consecutively approached and screened 
for eligibility. Sample size was based on consideration for a non-comparative observational 
study, and with a target of 70 patients [191].  However our primary outcome was 
population PK, where a sample size ≥ 50 is considered reasonable [192]. To increase the 
power of the study, about 20 per dose group with intense samples or 30 per group with 
sparse sampling was needed [192]. 
3.5.2.2 Data collection for PPK study in children under five years   
The study was conducted between September 2013 and June 2014.  
Clinical and laboratory {malaria microscopy, filter spot for genotyping, hematological, 
biochemical and pharmacokinetic} baseline data were collected. Thereafter children were 
treated with standard AL doses {Dispersible Coartem
 ® 20mg A/120mg L: 5 to ≤ 15 kg 
received 1 tablet, and 15 to ≤ 25 kg received 2 tablets}. The six doses were scheduled at 
about 0, 8, 24, 36, 48 and 60 hours.   Doses were administered with milk {50ml / tablet} or 
maize porridge plus oil {50ml plus 1.5 ml oil / tablet} in case of co-enrolled participants in 
the nested comparative bioavailability study (III). All initial doses and at least one of the 
doses on subsequent dosing days were supervised.  A  population PK sampling design was 
used to obtain sparse samples (0.5 - 1 ml, 1 to 8 venous blood samples/ participant) during 
a 28 days follow up period at various times. All participants were scheduled for PK 
sampling, clinical and malaria microscopy follow up on days 0, 3, 7, 14, 21 and 28.  The 
primary outcome was population PK of LUM (IV). Efficacy outcomes and tolerability 
were secondary outcomes.   
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3.5.2.3 Population pharmacokinetic analysis  
Fifty five children contributed data to the PPK dataset. Several structural PK models (1, 2, 
and 3 compartmental models with first-order absorption and elimination, with and without 
Tlag for extravascular input) with varied error models were explored using nonlinear mixed 
effect approach NONMEM Version 7.3.0 (NONMEM, version 7.3.0, ICON, Hanover, 
MD). The final descriptive model for LUM (using NONMEM by ADVAN4) was a two-
compartment PK model with first order absorption with lag time and elimination; 
parameterized in terms of apparent oral clearance (CL/F), inter-compartment clearance 
(Q/F), and apparent volumes of distribution of central (VC/F) and peripheral (VP/F) 
compartments, and first order absorption rate constant (KA). First order conditional 
estimation method (FOCE) was used.  Subsequently the parent drug model was adapted 
with fixed KA and VC/F fixed to 1 for the metabolite.  The parent and metabolite were 
modeled sequentially (specified to NONMEM by ADVAN6 TRANS1 TOL=5).  
Model improvement was done for only the parent drug, LUM. This was achieved by 
inclusion of significant covariates. These were body mass index (BMI) and age for LUM 
CL/F. Age was included with incorporation of CYP3A4 ontogeny adapted from Johnson et 
al., 2006 [170]. Weight was incorporated in the LUM VC/F model. Incorporation of BMI 
into the CL/F model explained variability due to weight and stunting.  
       AGEAGEBMI FCLFCLFCLREF AGEAGEBMIFCLFCL /// 31.01)62.16/(//   
 WTC FVREFCC WTFVFV /)0.13/(//   
Where CL/F and VC/F are the typical values centred on reference median BMI of 16.62 
Kg/m
2 
and median body weight of 13.0 kg. A log additive residual error model was used. 
Model discrimination for nonhierarchical base model was based on significance of changes 
in the objective function {i.e., -2 x log likelihood (LL) which approximates to objective 
function value, α < 0.05 for covariate insertion for the forward step and <0.005 for 
backward deletion}, diagnostic plots of observed with predicted data and residual-time 
plots. The developed final model was tested for reliability using bootstrapping methods and 
evaluated using diagnostic plots, and prediction corrected visual predictive checks by 
comparing model predictions with observations [174].  
3.5.2.4 Assessment of malaria treatment outcome   
Malaria efficacy and adverse events were secondary outcomes in the PPK study (IV). Main 
assessment was day 28 PCR adjusted parasitological response. Malaria treatment outcomes 
was further categorized by day 28 clinical and parasitological response (PCR unadjusted) 
as adequate clinical and parasitological response (ACPR), early treatment failure (ETF),  
late parasitological failure (LPF) and late clinical failure (LCF) as described by WHO 
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[193]; To assess predictors (covariates included baseline characteristics and PK outcomes) 
of treatment outcome, logistic regression was done.  
3.5.3 COMPARATIVE BIOAVAILABILITY STUDY IN PEDIATRIC PATIENTS 
(III) 
3.5.3.1 Comparative bioavailability study design  
A food interventional, comparative bioavailability study (III), was nested in the 
observational PK study (IV). In an open label, parallel study design, a subset of children 
was block randomized in successive blocks of 4 to obtain subsequent balanced allocation. 
Randomization was done in two stages by dose block (1 and 2 tablets) and food 
intervention arms (milk or maize porridge plus oil) as described under section 3.5.2.2. We 
aimed at 12 children in each dose block / study food arm. Sample size was empirically set. 
In intensive pharmacokinetic study designs, 8-12 participants in each group provide 
sufficient data to test for differences in 2 independent groups, at an adequate power (1-β) of 
80%, at α of 5% [194]. This has been previously demonstrated in a LUM bioavailability 
study [130]. 
3.5.3.2 Data collection for comparative bioavailability study  
Additional parental/guardian consent for co-enrollment was sought if a child enrolled for 
the PPK study was aged  >1  to ≤5 years and if parent was willing to stay and have their 
child participate in intensive sampling activities on Day 0.  
Patients received standard AL treatment regimen and supplemented with food with 
comparable fat content (3.4.3), either milk {A, standard arm} or maize porridge plus 
vegetable oil {B, experimental arm} as described under section 3.5.2.2.  
On Study Day 0, a baseline sample was collected before the first dose (0), thereafter 
intensive PK sampling (1ml) was done at 1, 1.5, 2, 3, 4, 6, 8 hours after the first dose. 
Thereafter patients completed their follow up in the PPK study (IV).  
3.5.3.3 Data analysis for comparative bioavailability study  
Individual PK data were assembled and profiles were examined for patterns of absorption.  
Statistical and Pharmacokinetic evaluations:  Lumefantrine PK outcomes (Tlag, Cmax, Tmax 
and partial areas under concentration-time curve) were determined as described under 
3.4.4. The primary endpoint was LUM exposure up to 8 h after the first dose (AUC0-8h). 
Relative oral LUM bioavailability was assessed with two group mean comparison with 
unequal variance t-test (Welch test, p < 0.05) using log transformed AUC0-8h estimates 
(STATA version 12.1 (1985-2011, StataCorp LP)). Secondary outcomes included day 7 
concentrations (C(LUM)D7), LUM exposure between days 7 and 28 (AUCd7-28) and clinical 
outcome as described in section 3.5.2.4.  
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3.6 DEVELOPMENT OF ANALYTICAL METHOD FOR LUMEFANTRINE 
AND METABOLITE (II) 
A sensitive method for quantification of LUM and its metabolite, DBL was necessary to 
allow use of small volume plasma samples among children treated with AL. In anticipation 
of low LUM levels among pediatric patients beyond day 7, the previous in house, filter 
paper method with HPLC-UV detection had LLOQ of 300nM for both LUM (159ng/ml) 
and DBL (128 ng/ml) would not be sensitive enough for the anticipated low levels [126].  
A bio-analytical method (II) was developed at the Therapeutic Drug Monitoring 
Laboratory, at the Division of Clinical Pharmacology, Karolinska University Hospital, 
Huddinge, Stockholm Sweden. 
Chemical use and sample preparation.  The target plasma volume was set to 100 µl. The 
choice of solvents was based on literature and physicochemical properties of LUM, which 
is highly lipid soluble and highly bound to plasma lipoproteins [114]. Protein precipitation 
was the preferred method, to avoid laborious extraction procedures. Varying types and 
concentrations of solvents were explored for extraction and mobile phases in order to 
achieve the best chromatographic separation. Acetonitrile (100%) yielded the best results 
for a one step extraction protein precipitation method. Methanol : DMSO (1:1) were used 
for LUM and DBL (Figure 2i) stock and intermediate solutions, while working calibrators 
and controls were spiked with known concentrations in previously tested drug-free plasma.  
(a) (b)  
Figure 2i. Structure of lumefantrine (a) and desbutyl-lumefantrine (b) 
Extraction was done by precipitating 100 µl plasma using 400 µL acetonitrile containing 
54.7 ng/mL of deuterated LUM (LUM-d18) and 9.64 ng/mL of deuterated DBL (DBL-d9). 
These isotopes were labeled internal standard (IS) using deuterium at the butyl chains (II) 
(Figure 2ii). 
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 (c)     (d) 
Figure 2ii. Structure of deuterated lumefantrine (LUM-d18) (c) and deuterated desbutyl-
lumefantrine (DBL-d9) (d) 
At the start of method development, halofantrine was tested as an analogue structural IS, 
but dropped due to subsequent availability of isotope labelled  compounds with an 
advantage of overcoming matrix effects and ion saturation [188]. After 30 seconds of 
vortexing the samples , these were centrifuged for 5 minutes (4200 G) and 450 μL of the 
supernatant was transferred to new glass vials. Then 10 µL of the supernatant was injected  
for liquid chromatographic separation.   
Instrumentation and conditions. Chromatographic separation was carried out on a Hypersil 
Gold C18 column (20 × 2.1 mm, 1.9  μm,Thermo Scientific) with a Hypersil Gold C8 
guard column(10 × 2.1 mm, 5μm) at 30◦C. Chromatographic separation was optimized by 
exploring different solvents’ composition for mobile phases, as well as elution mode  
(isocratic/gradient), column temperature and flow rates.  Preferred solvents, acidic water 
(0.5% formic acid in water) and acidic methanol (0.5% formic acid in methanol) were used 
as mobile phase A & B using gradient elution at a flow rate of 0.5 ml/min. A stepwise 
gradient elution was optimized as follows: 32% of solvent A at 0 min, sloped to 12% of A 
at 2.00 min, then 32% again at 2.01 min until 2.2 min. Total run time was 2.2 minutes. 
Mass spectrometry conditions were positive electro spray ionization (ESI+) using multiple 
reaction monitoring, with two product transitions validated for LUM and DBL (II).  
Method validation. The quantitative method was validated according to standards 
guidelines for evaluating a method’s performance in regard to precision, sensitivity, 
accuracy, recovery and stability [195]. Dilution integrity was checked in preparation for 
calculation of levels exceeding upper limit of quantification. 
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3.7 OTHER LABORATORY METHODS 
3.7.1 High performance liquid chromatography (HPLC) methods  
Venous plasma LUM concentrations in the health volunteer study (I) were determined 
using an HPLC with ultraviolet detection (UV) technique with slight modification for 
plasma samples [126]. Plasma samples were vortexed them aliquots (100µl) were spiked 
with halofantrine as internal standard (50 µl, 144 µM in methanol). Acetonitrile (150µl) 
was then added and mixture vortexed for 1 minute, sonicated for 15 minutes and finally 
centrifuged at 3500 x g for 10 minutes. The supernatant (20µl) was injected and detection 
was done under chromatographic conditions as described by Ntale et al., 2008. The plasma 
method was linear over a range of 52.9 – 2645 ng/ml, with intra-day and inter-day 
coefficients of variation < 11% and <13% respectively. The lower limit of quantification 
for LUM (LLOQ) was 100nM (52.9ng/ml) for the modified plasma method.  
3.7.2 Malaria microscopy 
Blood smears {BS} for malaria microscopy were stained with 2% Giemsa (I, III, IV). In  
thick BS, parasites were counted against 200 white blood cells (WBC) . Parasite density 
was calculated as “asexual parasites counted against  200 WBC multiplied by 40” /µl, with 
an assumption of 8000wbc / µl [193]. Thin BS for species identification was done only on 
Study day 0 and day of parasite re-appearance (III, IV). Each slide was read independently 
twice on Study day 0, on day of parasite re-appearance and for some randomly picked 
slides (10%) on any other day. Discrepancies were resolved by a 3
rd
 read. 
3.7.3 Malaria genotyping 
To differentiate between recrudescence and re-infection, paired filter paper blood samples 
[from day of treatment initiation and day of failure] were identified (III, IV). Parasite 
genotyping was done using nested polymerase chain reaction (PCR) characterization of the 
highly polymorphic P. falciparum  merozoite surface proteins 2 gene (MSP-2) [196].  
3.8 ETHICAL CONSIDERATIONS  
Ethical permits for the study and shipment of specimen were obtained from Makerere 
University School of Medicine - Research and Ethics Committee (SOMREC 2009-54) and 
the Uganda National Council for Science and Technology (HS 567).  The trial was 
registered at ClinicalTrials.gov {NCT01944189}. Informed consent was provided from 
adult volunteers and parent/ guardian of children. Good clinical practice and good 
laboratory practice standards according to ICH E6 guidelines were observed throughout the 
entire study period. 
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4 RESULTS 
4.1  EFFECT OF FOOD ON ORAL BIOAVAILABILITY OF LUMEFANTRINE 
4.1.1 Effect of food on oral bioavailability of lumefantrine in adult volunteers (I) 
4.1.1.1 Adult volunteers  
Thirteen Ugandan healthy volunteers (male {84.6%}, age and body weight ranged between 
20- 26 years and 43-85 kg) participated in the four period cross-over study. Forty five 
individual concentration-time profiles (fasted state /water, A: n=12, milk, B: n=11, maize 
porridge, C: n=11, maize porridge plus vegetable oil, D: n=11) were available for 
pharmacokinetic analysis (section 3.1.1.2). A total of 10 /13 completed participation in all 
arms thus provided matched data for relative bioavailability comparisons. 
4.1.1.2 Relative oral bioavailability of lumefantrine with food in adult 
volunteers 
The extent of LUM absorption was comparably increased by fat containing food, B and D 
{median (range): Cmax , 2 081 vs 3 827 nmol/L , p=0.059;  and AUC0-48: 47.5  vs 76.8 
hr*µmol/L, p=0.14, for B and D respectively} (Figure 3, Table 2). Similarly poor 
absorption of L was observed after intake without fat, with no differences in fasted state, A 
compared with C (Figure 3, Table 2).  
With B (milk) as reference, when AL was given with D (maize porridge with oil), the 
bioequivalence criteria {ratio of means ranging 0.80 – 1.25} was met and exceeded {ratio 
of means [90%CI]: 1.20 [0.85 – 1.69] and 1.25 [0.84 – 1.88] using dependent variables 
AUC(0-48) and Cmax respectively}. Whereas when compared to groups B, LUM exposures 
while participating in both A and C did not demonstrate acceptable levels of 
bioequivalence (Table 2) (I). 
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Figure 3. Median plasma lumefantrine concentrations over time in healthy adults following an oral 
single dose of artemether (80mg)-lumefantrine (480mg) under different conditions. {▲: fasted state (A, 
n=12), ◊ (grey filled) : milk (B, n=11), □: maize porridge (C, n=11), X:maize porridge plus oil (D, n=11)} 
 
 
Table 2. Relative bioavailability of lumefantrine after a single oral dose of AL (80mg, 
artemether, 480mg lumefantrine) with different food combinations   
Dependent 
Variable 
Formulation Variable : Food   Ratio of means 
(90%CI) 
          (0.80-1.25) 
Reference          Test   
 N=10
 b
  N=10
 b
    
AUC0-48 
(hr.µmol/L) 
 
B 47.5 (29.7-106.4)  A 14.6 (7.3- 78.5) 0.30 0.21 – 0.42 
   C 11.5 (4.8- 29.7) 0.22 0.16 – 0.32 
   D 76.8 (36.4-158.4) 1.20 0.85 – 1.69 
       
Cmax 
(μmol/L) 
 
B 2 .08 (1.62 – 4.36) A 0.87 (0.28- 4.00) 0.34 0.22 – 0.51 
  C 0.70 (0.18 – 1.28) 0.23 0.15 – 0.35 
    D 3.83 (2.05 – 5.60) 1.25 0.84 – 1.88 
       
       
    Median (range) values for estimates
 
     b
: reduced sample size because of inclusion of only matched data, 10/13 participants  
    completed participation in all 4 food study arms {A: fasted state, B: milk,    
    C: maize porridge, D: maize porridge plus oil}. 
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4.1.2 Comparative bioavailability study in pediatric patients (III) 
4.1.2.1 Patients: Pediatric Study Participants (III, IV) 
A total of 70 children with uncomplicated P. falciparum malaria were enrolled, 41 of who 
were randomized to participate in the nested comparative bioavailability study (21 to milk 
and 20 to maize porridge plus oil). Thirteen children were excluded due to significant 
baseline LUM (Figure 4). Eight of who had been co-enrolled in the comparative 
bioavailability study. Patients’ characteristics are summarized in Table 3 (II –IV).  
 
 
Figure 4.  Trial Profile 
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Table 3. Baseline characteristics of pediatric study participants  
Description Pharmacokinetic 
Study ( 6 doses) 
Nested Comparative Bioavailability study 
(Post-first dose) 
 All, evaluable Subset 
evaluable   
Milk 
(A) 
Maize porridge + 
vegetable oil (B) 
N 55 33 16 17 
Dose blocks     
     1 tablet, <15kg 38 19 10 9 
   12 – 24 mo(n) n=9    
>24 – 59 mo(n) n=29    
     2 tablets, ≥15kg   17 14 6 8 
   12 – 24 mo(n) n=0    
>24 – 59 mo(n) n=17    
     
Male, All 33 (57.9%)  8 /16 11 / 17 
     
Age, months (mo)      
    All 35.5 (13.5 – 59.7)  35.8 (16.4-57.7) 41.9 (17 -59.7) 
     1 tablet 28.6 (13.5 - 57.7)*
1a
  29.9 (16.4-57.7) 29.0 (17.0 - 50.6) 
     2 tablets 47.6 (35.1- 59.7)*
1a
  42.6 (35.1- 48.5)*
2
 53.2 (36.7 - 59.7)*
2
 
     
Weight, kg      
   All 13.0 (9.0 – 17.4)  13.6 (9.5-16.0) 14.5 (9.5 -17.4) 
     1 tablet 12.0 (9.0 -14.8)  12.0 (9.5 -14.0) 11.4 (9.5 -14.5) 
     2 tablets 15.2 (15.0-17.4)  15.0 (15.0-16.0) 15.6 (15.0-17.4) 
     
Height, cm  88.2 (69.5 – 104.7)    
     
Total LUM dose, mg/kg First LUM dose, mg/kg/dose 
All 62.4 (48.6 - 96.0)  11.5 (8.6 - 16.0) 12. 6 (8.3 - 16.0) 
     1 tablet  60.0 (48.6 -79.8) *
1L
  10.0 (8.6 - 12.6) 10.5 (8.3 - 12.6) 
     2 tablets  93.0 (82.8 - 96.0)*
1L
  16.0 (15.0 -16.0) 15.4 (13.8 - 16.0 ) 
Baseline 
parasitemia, /µL   
11340 (8 – 688640)  14460 (16 - 
503360) 
936 (16- 127120) 
All values are stated as median (range)    *1a, *1b,*1L, *2: p value 
of <0.0001  
Ex: 22 participants participated in only population PK activities 
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4.1.2.2 Comparative oral bioavailability of lumefantrine in pediatric patients 
(III) 
Primary outcome. Thirty three children were evaluable. (Figure 4, Table 3). After the first 
AL dose, early LUM exposure (AUC0-8h) was comparable between the two arms A {milk, 
n=16} and B {maize porridge plus oil , n=17}, (GM {95%CI}: 6.01 h*μg/ml {3.26-11.1} 
vs 6.26 h*μg/ml {4.5 -8.43}, p=0.9 for A and B respectively) (Table 4). Less inter-
individual variability in AUC0-8h was observed in B (p=0.01) compared to A (Fig. 5, Table 
4).  
 
 
Figure 5. Distribution of AUC0-8h [h*ng/mL] estimates (log –transformed), after   
the first artemether-lumefantrine dose across food arms (A & B) and dose groups 
(1 or 2 AL Tablets). Reference midline in box is a median value (IQR) with 
whiskers as non-outlier upper and lower range, and “*”as outliers.   
Food: A: Milk, B: Maize porridge plus oil (all participants dosed with 1 or 2 
tablets). Dose groups: 1 =1 tablet containing 120 mg LUM; 2 = 2 tablet total 240 
mg LUM 
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Table 4: Comparison of lumefantrine pharmacokinetic estimates after oral doses of 
artemether-lumefantrine with different food among under five year old children with 
malaria   
 A 
Milk 
B 
Porridge plus 
Oil 
p value 
All 16 17  
     1 tablet, <15kg  10 9  
     2 tablets ≥15kg   6 8  
LUM/dose, 
mg/kg/dose 
11.5 (8.6 - 16.0) 12. 6 (8.3 - 16.0) 0.9
 w
 
    
Parameters after first dose   
AUC0-8h, h.μg/mL    
All, GM(95%CI) 6.01 (3.26 – 11.1) 6.26 (4.65 – 8.43) 0.9
t
 
    
Dose Corrected AUC0-8h, h/L/kg  
All, GM(95%CI) 0.49 (0.27 - 0.86) 0.49 (0.36 -0.66)       0.9972
 t
 
    
Parameters after multiple doses  
Day 7
 o
, ng/mL        350 (136 – 9647), 
n=14
o1
 
376 (158 – 6142), 
n=13
o2
 
0.73
 w
 
    
AUCd7-28, h 
μg/mL  
50 (20 – 493), n=13 87 (27 – 435), 
n=13 
0.59
 w
 
    
     GM (95%CI): geometric mean and its 95% confidence interval  
     t: t test with unequal variance 
     w: Wilcoxon rank-sum (Mann-Whitney) test. *=0.02      **=0.006 
     O: Day 7 including outliers. If excluded o1= 9647, then A (n=13, 343 (136 – 1827 ng/ml)). 
     if excluded o2=6142, then B (n=12,  342 (158 – 1672) ng/ml).   
     AUCd7-28 : Truncated area under the concentration curve between 7 and 28 days 
 
 
 
Secondary outcome. Upon completion of multiple doses, C(LUM)D7 and area under the 
concentratin curve between 7 and 28 days (AUCd7-28) were comparable across the 2 food 
arms (Table 4). Notably, LUM exposure was significantly higher among bigger children 
{> 15 kg} receiving 2 tablet dose than smaller children {< 15 kg} dosed with 1 tablet 
{median C(LUM)D7: 505 [192-9647] vs 289 [136-1826]  ng/ml, p=0.02 and AUCd7-28 : 108 
[42-493] vs 41 (20 -167) hr-μg/ml, p=0.006 for 2 and 1 tablet respectively}. However 
LUM dose-adjusted exposures were not significantly different (III). 
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4.1.3 Comparison of adult volunteers and pediatric patients findings 
Among healthy adults, partial area 8 hours after a dose {AUC(0-8 h)} correlated well with 
that truncated at 48 hours {AUC(0-48 h)} (τ =0.42, p=0.007). With reference to early partial 
exposure of LUM at 8 h, AUC(0-8 h) did not significantly differ, when compared across 
study populations for milk (median: 5.4 μg/ml vs. 6.6 μg/ml, p=0.77 for adults and 
pediatric patients respectively) and maize porridge plus oil (8.4 μg/ml vs. 7.4 μg/ml, 
p=0.31, for adults and pediatric patients respectively) (Table 5). Notable differences 
included weight adjusted LUM dose and delayed Tlag in sick children compared to healthy 
adult volunteers in the milk group (Table 5).  
Table 5. Comparison of lumefantrine pharmacokinetics after a single oral dose of  
AL among healthy adult volunteers and children with uncomplicated P. falciparum 
malaria 
Description Adult volunteers 
 
Single dose 
Pediatric Patients  
(< 5 year) 
After first dose 
p value 
n    
Milk 11 16  
Maize porridge plus oil 11 17  
Lumefantrine dose, mg/kg/dose 
  
Milk 8.0 (5.9 - 10.9) 11.5 (8.6 - 16.0) 0.0006 
Maize porridge plus oil 8.1 (5.6 - 11.2) 12. 6 (8.3 - 16.0) 0.0002 
Tlag, h 
   
Milk 1.02 (1.00 – 2.00) 1.87 (0.92 - 3.1) 0.004 
Maize porridge plus oil 1.02 (1.00 – 2.05) 1.55 (0.65 - 3.02) 0.11 
Tmax, h 
   
Milk 6.00 (4.00 – 24.0) 6.17 (3.13 - >8.0)  0.9 
Maize porridge plus oil 6.00 (4.00 – 24.0) 7.85 (4.03 - >8.0)  0.2 
Cmax, ng/ml 
   
Milk 1101 (857 - 2308) 1836 (177 – 11545) 0.69 
Maize porridge plus oil 2024 (1084 - 2963) 1718 (636 -  6684) 0.62 
AUC(0-8 h) , h*μg/ml 
   
Milk 5.4 (4.2 -  10.1) 6.6 (0.5 -  36.2) 0.77 
Maize porridge plus oil 8.4 (3.4 – 14.5) 7.4 (1.6 -  11.9) 0.31 
Values are Median (range) 
AL tablet contains 20 mg artemether and 120 mg lumefantrine 
Children: < 15 kg dosed 1 tablet of AL, ≥ 15 - < 25 kg dosed 2 tablets 
Adults: ≥35 kg dosed 4 tablet of AL 
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4.2 PHARMACOKINETICS OF LUMEFANTRINE AND DESBUTYL-
LUMEFANTRINE IN PEDIATRIC PATIENTS (IV) 
4.2.1 Population pharmacokinetics of LUM and DBL in < 5 year old children (IV) 
Fifty five children were included in the population PK evaluations contributing 453 and 
233 data points for LUM and DBL respectively (Figure 4, Table 3). According to the 
current fixed weight-based AL dosage, variation in LUM total dose ranged between 48.6 
and 96.0 mg/kg (Table 3). Children {≥ 15kg, n=17} dosed with 2 tablet notably received 
higher LUM dose {median: 93 vs 60 mg/kg, p<0.00001} and were older {median age: 46.6 
vs 28.6 months, p<0.00001) than those dosed under 1 tablet dose group {< 15kg, n=38} 
(Table 3). Twenty three children (40.3 %) were stunted, and 2 children (3.5 %) were 
underweight. Overall median BMI was 16.6 (range: 13.6 – 26.2) kg/m2 and with no 
difference between children < 24 months {16.6 (range 15.4 – 22.4) kg/m2} and those > 24 
months {16.6 (range 13.6 – 26.2) kg/m2}. 
A two compartment PK model adequately described both the PPK of LUM and DBL 
(Figure 6). Detailed model development trail and diagnostics are presented in IV.  
 
 
 
Figure 6. Goodness of fit plots for final lumefantrine and metabolite in < 5 year old 
Ugandan children. Observed against population and individual predicted concentrations on 
a logarithmic (10) scale.  
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Inter-subject variability of CL/F was partly explained by BMI and age (incorporating 
CYP3A4 ontogeny) (Table 6). The CL/F of LUM decreased with increasing BMI (Figure 
7). Detailed paired plots showing other covariates and PK outcomes in (IV). The BMI 
(weight {kg} / (height {m})
 2
) explained both weight and height thus catered for weight and 
stunting (height for age) as significant covariates for CL/F. BMI alone in the CL/F model 
explained 5% of the inter-subject variability (from 29% in base model to 24% with BMI in 
CL/F model) and when age was also included, they both reduced unexplained inter-subject 
variability in the final CL/F model by 6.8 % (from 29% in base model to BMI in CL/F 
model : 24% and BMI and age in CL/F model:  22.2%). Inter-subject variability of VC/F 
was explained to a certain extent by weight. The inter-subject variability in VC/F decreased 
from 83.7% in the base model to 78.9% in the final VC/F model with weight included. 
 
Table 6. Summary of significant factors in the covariate analysis 
Run Model OFV  cf. 
 
df 
LLD Sig. 
1 Base model - one residual error model 341.035 
 
  
  2 Base model - two residual error models 309.077 1 1 -31.958   yes
Forward Stepping (p=0.05) 
3 CL/F~WT 308.670 2 1 -0.407 no 
4 CL/F~STUNTING 294.445 2 1 -14.632   yes 
5 CL/F~BMI 294.401 2 1 -14.676   yes 
6 CL/F~BMI & VC/F~WT 292.746 5 1 -1.655 no 
7 CL/F~BMI, CL/F~AGE; VC/F~WT 287.934 6 1 -4.812   yes 
Backward Elimination (p=0.005) 
8 "- C/F~AGE" 292.748 7 1 4.814   yes 
9 "- C/F~BMI, CL/F~AGE" 307.643 7 2 19.709 yes 
9 "-CL/F~BMI,-CL/F~AGE; - VC/F~WT 309.077 7 3 21.143   yes 
 
CL/F:  apparent oral clearance, VC/F: apparent central volume of distribution,  
BMI: Body mass index, WT: Weight (kg) AGE: Age in months,  
Sig.: Significant if LLD (change in 2 log likelihood value for compared models) for 1, 2 and 3 df (degrees 
of freedom) is >7.88, >10.6, >12.84 at p<0.005 or >3.84, >5.99, >7.81 at p<0.05 respectively.  
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Figure 7. Plots showing the relationship between apparent oral clearance( CL/F) and significant 
covariates: (a) body weight,  (b) age and (c) body mass index (BMI). Open blue squares: age = < 24 
months; filled red circles: age = > 24 months.  
 
Typical values for LUM and DBL are summarized in the Table 7.  The population mean 
Tlag (ALAG1) for LUM was 0.98h and LUM mean absorption rate constant was 0.0383
 
(RSE of 11.9%). 
Table 7. Summary of population pharmacokinetic parameters estimates for 
lumefantrine and desbutyl-lumefantrine in children under five year old with malaria  
Description Population mean  RSE
#
 IIV (%CV) RSE
#
 
    Lumefantrine 
CL/F (L h
-1
) 3.19  24.4% 0.0492 (22.2) 31.3% 
   CL/FAGE -0.423 27.2%   
   CL/FBMI -1.10  -   
     
VC/F (L) 28.1  18% 0.623 (78.9) 30.7% 
   VC/FWT 1.06   -   
     
Q/F (L h
-1
) 0.176  15.6%   
VP/F (L) 58.4 16.2%   
KA (h
-1
) 0.0383 11.9%   
ALAG1 (h) 0.98 - 0.0029 (5.39)  
     
    Desbutyl-lumefantrine 
CLM (L h
-1
) 0.0807 -   
 
CL/F, Q/F, KA, VC/F, and VP/F are typical values of LUM apparent oral clearance, inter-compartment 
clearance, absorption rate constant , apparent volume of distribution of central and peripheral 
compartment at the reference BMI (16.62 kg/m
2
)and weight (13.0 kg).   
IIV: Inter-individual variability. CL/FAGE , CL/FBMI , VC/FWT :Effect of age and BMI on CL/F, effect of 
weight on VC/F. CLM : rate of elimination of the metabolite.  
#
 : 
 based on 300 bootstrap runs, relative standard errors (RSE = 100 × (standard error/mean)).  
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In this study, the CL/F of LUM was found to decrease with age, from one to 5 years old 
(Figure 7). On average, the change in LUM CL/F from “>1 - 2 years old” to “> 2 years 
old” was approximately -20.6%. The population median CL/F from empiric Bayesian 
individual parameter estimates which was 1.33 L/hr.  Comparing individual LUM CL/F 
estimates among children (38 / 55) receiving the same dose (< 15 kg, 1 AL tablet), children 
who were older than 24 months {n = 29} had significantly lower estimates than their 
younger counterparts {< 24 months, n = 9} (median {range}: 1.27 {0.79 – 1.91} vs 1.6 
{1.05 – 2.14} L/h, p=0.046).  With reference to the median BMI of 16.62 kg/m2 for our 
dataset, the estimated LUM CL/F for a typical 12, 24, 36, 48, and 60 months old were 1.69, 
1.46, 1.32, 1.23 and 1.16 L/hr respectively. Thus, LUM CL/F decreased by 31.4% from 12 
to 60 months of age.   
Desbutyl-lumefantrine. The fraction of DBL formed was estimated to be 0.0542%. The 
rate of elimination of DBL was estimated to be 0.0807 L/h. Transfer rate constant of DBL 
from central to peripheral (K45) and from peripheral to central metabolite compartments 
(K54) were 0.0448 and 0.00804 h
-1
.  
The visual predictive check confirmed good predictive performance of the final 
pharmacokinetic LUM and DBL model (Figure 8). 
 
 
Figure 8. Prediction Corrected Visual Predictive Check of the final pharmacokinetic lumefantrine 
(LUM) and desbutyl-lumefantrine (DBL) model. Open blue diamond shapes: observed 
concentrations of LUM and DBL. Solid and dotted line: shows 50
th
, 2.5
th
 and 97.5
th
 prediction 
intervals with associated 95% confidence intervals.  
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4.2.2 Secondary pharmacokinetic outcomes  
In this < 5 year old population, median C(LUM)D7 ( n=46) was 441 (136-9647) ng/mL. 
Notably C(LUM)D7 was significantly higher among children dosed 2 tablets compared to 
those dosed with 1 tablet {median: 586 (192 – 9647) vs 315 (136 – 5418) ng/ml,  p=0.04}. 
For children aged < 24 months and those > 24 months, C(LUM)D7  were not significantly 
different (p=0.09) (Table 3). All the children who received 2 tablets of AL exceeded 280 
ng/ml, except for one child (1 / 13) whose C(LUM)D7 was 192ng/ml. Of the children who 
received 1 tablet of AL, 15% (5 / 33) had C(LUM)D7 <175 ng/ml and  36% (12 / 33) had 
concentrations < 280 ng/ml. 
Overall computed AUC (AUC0-inf) was significantly higher among children who received 2 
tablets compared to those dosed with 1 tablet (median AUC0-inf : 181 vs. 93 hr*μg/ml,  
p<0.00001) but  LUM dose-adjusted AUC0-inf was not significantly different (p= 0.0544) 
(Figure 9). The observed non-significant increase in dose adjusted AUC among older 
children receiving higher doses (240mg vs. 120mg) may imply that absorption does not 
increase proportionately with increased doses. However notably, comparing children in the 
same “1 AL tablet” dose group, those aged > 2 years {n=30} had higher AUC(0-inf) {95 vs. 
75 hr*μg/ml p=0.037} and dose adjusted AUC { 0.79 (0.56– 1.26 ) vs. 0.63 (0.47 – 0.95)  
hr/mL/kg , p=0.049} than their counterparts aged < 2 years (Figure 9). This is in line with 
the fact that CL/F is lower among children > 24 months.  
The day 7 DBL concentrations ranged from 0 to 74.2 ng/ml (median of 14.7 ng/ml). The 
ratios of DBL / L UM varied between 1/40 - 1/10. 
 
 
Figure 9. Distribution of  LUM exposure (AUC0-inf and Dose adjusted  AUC0-inf ),  
after standard 6 doses of artemether-lumefantrine among under five year old children treated for 
uncomplicated malaria. Reference midline is the median.  
Dose groups (1 & 2): 1 tablet = 120 mg LUM, 2 tablets = 240 mg LUM. Age categories: 1= < 24 
months, 2= ≥ 24 months. 
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4.2.3 Treatment outcomes and relationship with pharmacokinetic outcomes    
Efficacy assessment as per intention to treat analysis was done. Day 28 PCR unadjusted 
treatment outcomes were as follows:  Out of the 70 children enrolled, 53 (81%) had ACPR, 
1 experienced ETF, 3 LPF, 1 LCF and 12 unknown parasitological outcomes, since smears 
were not done either due to earlier  withdrawal or lost to follow up. Per protocol analysis, 9 
children had unknown parasitological outcomes; 46 of 55 PPK evaluable children were 
evaluable for the clinical efficacy outcome (WHO Day 28 PCR unadjusted treatment 
outcomes) follows:  41 had ACPR, 1 experienced ETF, 3 LPF, and 1 LCF.  
Only one child of those with LPF had PCR verified parasite recrudescence  on day 28. This 
was a 47.6 months old child, 17.4kg, BMI = 17.3 kg/m
2
, initial parasitemia of 108,680/μl,  
and dosed 2 AL tablets with milk, total LUM dose of 84.7 mg/kg (14.1 mg/kg/dose). The 
child who experienced ETF developed danger signs on study day 1, despite reduction of 
parasite density by 89% and was rescued with intravenous (IV) artesunate.  He was 41.9 
months old, 10.5 kg, BMI=14.2 kg/m
2
 
 
,initial parasitemia of 63,720 /μl and dosed 1 tablet 
with maize plus oil, LUM dose of 11.5 mg/kg/dose.  
Overall, AL was well tolerated except for 2 children who experienced vomiting, and 2 
diarrhea. 
Treatment was completed by all the 70 children, including the one with early treatment 
failure whose AL treatment was resumed after IV artesunate. 
Only one of these children had PCR verified treatment failure and neither LUM (C(LUM)D7 
and AUC0-inf) nor DBL exposure was found to be a significant predictor of parasitologic 
failure. Among those with parasite re-infection, BMI was a predictor for parasite 
reappearance.  
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4.3  ANALYTICAL QUANTITATIVE METHOD FOR LUMEFANTRINE AND 
DESBUTYL LUMEFANTRINE (II)   
A LCMS/MS method was developed for simultaneous determination of LUM and DBL 
concentrations in human plasma (100 μl). Protein precipitation was the preferred 
extraction method using acetonitrile (400 µl) containing 54.7 ng/ml of LUM-d18 and 
9.64 ng/mL of DBL-d9 as internal standards. The validated measuring range was 21 – 
529 ng/mL for LUM and 1.9 – 47 ng/mL for DBL, with a linear regression coefficient > 
0.99 for the calibration curves of all runs. The minimum amount of plasma necessary was 
100 μl although smaller volumes were successfully tested including diluted samples with 
concentrations over the upper limit of quantification (II).  Inter- and intra-assay precision 
was < 10% coefficient of variation (CV) for all levels of both LUM and DBL. Accuracy 
was within -9% to +6% for all levels of both LUM and DBL. The LLOQ for LUM and 
DBL were 21 ng/ml (40 nM) and 1.7 ng/ml (4 nM), respectively. Retention times of 1.7 
minutes for LUM and LUM-d18 and 1.5 minutes for DBL and DBL-d9.  
The short total run time of 2.2 minutes, allows a high sample throughput. The method was 
successfully applied for plasma LUM and DBL determination in children under 5 years of 
age with uncomplicated malaria, up to 28 days after a standard 3-day treatment with AL. 
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5 DISCUSSION 
This thesis sought to optimize AL use in resource limited settings and also describe 
population PK of LUM in children < 5 year old with uncomplicated falciparum malaria. 
The overall aim was to provide the structural framework for a rational approach for re-
evaluating AL dosage guidelines for children less than 5 years of age.  
Effect of food on lumefantrine oral bioavailability 
It is well established that dietary fat is essential for augmentation of LUM absorption [72, 
129, 130]. In order to reduce the risk for development of resistance, it is essential to 
optimize drug exposure and avoid sub-therapeutic concentrations.  
We demonstrated that LUM absorption was comparably augmented when AL was given 
with milk (standard) or maize porridge fortified with vegetable cooking oil (experimental) 
(I & III). This is attributed to similar fat content. This was initially examined among 
healthy adult volunteers (I). Addition of fat to maize porridge increased LUM AUC (0-48) by 
600% compared with maize porridge alone. Whereas there was no difference between 
maize porridge alone and intake of AL under fasted state among adult volunteers. Both 
groups demonstrated lower ranges of LUM exposures relative to milk and maize porridge 
with oil (I). In agreement with previous studies [74, 75], we observed great inter-subject 
variability in LUM exposure. Greatest variance in adults was observed after dosing under 
fasted state (I). Despite the difference in variance of PK parameter estimates across the two 
food arms, it can be claimed that maize porridge with oil increased LUM absorption to the 
same magnitude as with milk in children with uncomplicated malaria (III). Notably among 
young children, less inter-individual variability in AUC0-8h was observed in the maize plus 
oil group compared to the milk supplemented group (p=0.01). This could be due to 
different effect on gastric emptying time for solid feeds compared to liquids [198]. In 
addition, the observed reduced risk for sub-therapeutic LUM concentrations in the maize 
plus oil compared to those in the milk group suggests an advantage from an efficacy point 
of view.  The clinical implications need to be further evaluated through larger effectiveness 
studies.  
Though African diet has been considered adequate for LUM absorption [197] and the 
manufacturer recommends that AL administration “should be followed whenever possible 
by food/drink (e.g., milk, formula, pudding, broth, and porridge)” [81]; we have 
demonstrated that commonly available African food with little or no fat content, such as 
maize porridge cannot be reliably recommended to augment LUM absorption. Addition of 
fat or cooking oil to porridge should be advised. 
Our food strategy aimed at prescribing minimal but sufficient volumes (50-100mL) of food 
to children, in order to ensure adequacy of fat content (>1.2g of fat) [130]. This is a 
practical approach as small children are unable to complete big portions of food [120].   
Laboratory techniques geared at enhancing solubility of lipophilic oral drugs [199] like 
LUM have been explored [200, 201].   However new technological innovations are likely 
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to take a long while to maximally exploit formulations with enhanced solubility. 
Consequently the importance of dietary fat remains critical to augment LUM absorption. 
Methodological considerations for the bioavailability studies  
In both adult volunteers and pediatric patients studies, it was not possible to use overall 
exposure {AUC(0 – infinity)} for bioavailability comparisons. Among adult volunteers, AUC(0- 
infinity) could not be determined in 23/45 individual profiles, because results for thawed 
samples collected were invalidated.  Restriction of evaluations to partial area between 0 to 
48 h post-dose {AUC(0-48 h)}, a point with available data in all patients was considered 
reasonable because it is likely that absorption was completed by 48 h (I). It has been 
reported that oral absorption of LUM among adults is almost complete by about 18 h [74]. 
Among adult volunteers’ profiles, we observed similar parallel trends in decline of 
concentration with time regardless of the food group (I). Therefore, it is unlikely that food 
intake affects elimination process. Among children with malaria, evaluations were 
restricted to 8 hours {AUC(0-8 h)}, prior to the second dose (III). This was justifiable 
because interference from cumulative drug absorption sets in with subsequent dosing [74, 
75]. In addition, it would not have been ethical and we could not delay the second dose 
among these pediatric malaria patients. The appropriateness of use of early partial area 
truncated at 8 hours was evaluated (Section 4.1.3, Table 5). Truncated exposure estimates 
after a single dose adequately evaluated effects of food on LUM absorption.    
The healthy volunteer crossover design provided an advantage of matched comparisons 
where each participant was their own control. In the crossover study, average 
bioequivalence techniques were used to assess relative bioavailability (I).  For the pediatric 
patients study which employed parallel design, traditional average bioequivalence 
techniques could not be employed due to lack of proportional evaluable subjects per dose 
block in each arm (III). The relative bioavailability was appropriately assessed using the 
two one-sided tests for comparisons of unmatched two samples [202]. In addition dose 
adjusted exposures were compared.   
In general, wide variation in exposure was observed within and between groups. In addition 
individual differences while participating in different food arms were observed in the 
preceding volunteer study (I). However it was not feasible and we could not plan to assess 
“interchangeability” (using population or individual bioequivalence techniques (Section 
1.6.1.1.2)) of use of either food supplement among patients. Selection bias in the pediatric 
study (III) was minimized by block randomization in two stages, by dose group (weight 
based) and food arm. Unfortunately we did not recruit targeted numbers for the 2 tablet 
dose group.  This arose because we could not find enough numbers of heavier of children 
with malaria, weighing > 15 kg. Most children were appreciably small, light and short for 
their age (40% were stunted), but they didn’t qualify to be categorized as underweight or 
wasted according to WHO standards [203].  
It was for obvious reasons, impossible to ensure optimal fasted conditions (8 hours) before 
participation in the bioavailability study among sick children. Gastric emptying among 
children may be faster than that in adults [198].  
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Quantitative bioanalytical lumefantrine and desbutyl-lumefantrine method   
A simple, fast and sensitive LCMS/MS method for quantification of LUM and DBL in 
small plasma volume was developed. The simplicity was achieved by the single extraction 
step, using acetonitrile for protein precipitation, which allows injecting a 10 μl supernatant 
aliquote in the LC-MS/MS system. Another advantage is that the developed method 
requires minimal amount of plasma (100 μl) which is obtained from approximately twice as 
much whole blood (200 μl) which makes repeated sampling possible in pediatric studies.  
Further testing proved that it is feasible to use plasma volume as small as 25 μl. The short 
total run time allows a high throughput. The method was successfully applied for plasma 
LUM and DBL determination in children under 5 years of age with uncomplicated malaria, 
up to 28 days after a standard 3-day treatment with AL. Determination of LUM and DBL 
in dry blood spots would be desirable for field studies.  
Population Pharmacokinetics among under five year old malaria patients 
The PPK of LUM and its metabolite, DBL was adequately described using a two-
compartment PK model with first order processes. This is the first report characterizing the 
PPK of LUM and DBL among children under five years of age. Few LUM PPK studies 
among children have been done [120, 178]. However this is the first LUM population-
based PK model to incorporate ontogeny of LUM metabolizing enzymes in the CL/F 
model. The activity of CYP3A4 is very variable especially with age [164]. High inter-
individual variability in LUM disposition has been reported [72]. In our study, inter-subject 
variability in LUM CL/F was partly explained by BMI and age, while that in VC/F was 
partially explained by weight. The LUM CL/F was slightly higher among children < 2 
years, and decreased with age from 2 to 5 years old.   This trend is consistent with the 
report from the meta-analysis of C(LUM)D7 where lower concentration were observed in 
children below 2 years compared to those above 2 years of age, regardless of nutritional 
status [60, 169]. The observed trend of decreasing LUM CL/F with age after infancy has 
also been similarly reported for some other CYP3A4/5 substrates [165-167].   
Our findings suggest that stunting is responsible for some of the unexplained variability in 
CL/F. Weight, on its own, had no effect on LUM CL/F. The effect of malnutrition on LUM 
PK disposition could not be assessed exhaustively since none of the children could be 
categorized as wasted, only 2 were underweight and 40% were stunted (height for age z-
scores < -2). Incorporation of BMI (a composite of weight and height) into CL/F model 
explained variability due to weight and stunting among these < 5 year old children. The 
LUM CL/F increased as BMI decreased. As described above, weight alone did not explain 
any inter-individual variability in the CL/F model but explained 4.8% of the variability in 
VC/F. Weight was not a significant covariate, but the inclusion and retention in the VC/F 
model was for allometric purposes (Table 6). This is contrary to what was reported in an 
earlier study among children and adults, where weight was the most influential covariate 
and impacted positively on both CL/F and VC/F [178]. Other significant covariates for 
CL/F including age, height and in addition sex were also identified in that study [178].  An 
earlier dose finding trial and one of the very first LUM PPK studies among older children > 
15 years and adults showed that CL/F increased with weight above 50 kg and age above 24 
years [72]. In a recent study among children less than 2 years, age was shown to have had a 
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positive influence on LUM bioavailability but it is not reported whether weight affected 
CL/F. However their CL/F model included allometric scaling in relation to weight. Other 
PPK studies among children ranging 1 to 10 years did not identify any patient 
characteristics as being influential on CL/F or VC/F [117, 120]. 
Our estimated CL/F for a typical child 1 and 2 year old with reference to median BMI of 
16.6 kg/m
2
 approximates to the estimates reported by Tchaparian et al., for children 
between 1 and 2 years of age (Table 1) [177]. Their CL/F population estimates are in 
agreement with our findings, where children younger than 24 months and with lower 
BMI had higher CL/F. The children studied [177] weighed much less (median weight 
was 8.43 kg, range 6.1 -13.0 kg, and no BMI reported) [177] than our children in the age 
range of 1-2 years (median 11.5 {range: 9-14.5} kg). Other pediatric studies reported 
much higher CL/F estimates (Table 1) [117, 120]. Some of the difference may have been 
caused by shorter sampling duration not appropriately encompassing the terminal 
elimination phase, differences in age, BMI, and the absence of allometric scaling for the 
PK parameters. For adult populations, other than age, variation may be due to pregnancy 
[118, 179] and drug- drug interactions [154, 180]. 
Estimates for VC/F varied much more than those of CL/F between studies. In our 
analysis, the inter-individual variability in VC/F remains greatly unexplained.  
Desbutyl-lumefantrine PPK has been described in previous studies [117, 178-180], one of 
which was among children [117]. Some approaches, assumed 100% conversion of parent 
drug to metabolite [117, 180]. This may have resulted in biased estimation of DBL 
population PK parameter estimates. The rationale for assuming 100% conversion of LUM 
to DBL was not provided by the authors. Thus, we estimated the fraction of metabolite 
formed as part of the estimation of PK of DBL.  
Methodological considerations for the PPK studies  
The population analysis lacks information among children less than 1 year as these were 
not included. Assessment of PK-PD relationships was constrained given the small study 
population and the fact that we only had a few (n=3) parasite re-infections and only one 
with parasite recrudescence. The sample size was adequate for PK evaluations, mixed 
sampling design (intensive and sparse) was performed and several samples (2-8) were 
provided by most of the patients [204]. It was intended to cater for non-comparative 
assessment of efficacy in the study group as well. Unfortunately, the sample size was not 
adjusted for loss to efficacy follow up. Of note is the fact that logistic regression 
performed with available covariates, only yielded BMI as a predictor for parasite re-
appearance. In the logistic regression, both re-infections {n=3} and recrudescence {n=1} 
were considered parasitologic failure. Note that BMI is also major predictor of CL/F, 
implying that those with lower BMI had higher CL/F. This suggests that children with 
lower BMI may need higher dose.  
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Clinical outcomes and perspectives on clinical implications of our findings 
We cannot overlook the efficacy of the current weight-fixed dosing regimens. Given our 
study population (evaluable n=55), only one recrudescence was registered. This was a child 
(17 kg, 47.6 months) dosed with 2 AL tablets (total LUM dose of 84.7 mg/kg). The child 
with the lowest C(LUM)D7 was one of those with parasite re-infection, and the only one who 
experienced late clinical failure and. The 3 children who had PCR confirmed re-infections 
were older than 24 months but small with BMI much less than the population median (< 
15.5 kg/m
2
). Given the fact that their weight was < 15kg, they were dosed with 1 AL tablet 
which resulted in total LUM weight adjusted dose of ≤ 60 mg/kg (≤ 10mg/kg/dose). Our 
observation is in agreement with an earlier report of total LUM dose between 50 and 79 
mg/kg being a predictors of low C(LUM)D7 and increased risk of malaria re-infection [80]. 
This further highlights the fact that children with lower BMI may need higher dose. 
However LUM has been shown to exhibit dose dependent absorption in animal studies 
[112] and similarly saturable LUM absorption has been reported in healthy volunteers 
[130]. We observed slight, non-significant increase in exposure (AUC-dose normalized) 
with increasing dose which indicates that saturable absorption might exist also in children. 
Allowing more time for prolonged LUM absorption, before administration of subsequent 
dose may be beneficial. Extended dosage schemes were earlier suggested for vulnerable 
populations at risk of lower LUM exposure [121, 149].  
 
Though increasing LUM dose may pose a challenge, our findings highlight that exploration 
of age specific AL dose schemes, adjusted for BMI may provide rational AL doses for 
under five year old children regardless of nutritional status. 
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6 CONCLUSIONS AND RECOMMENDATIONS 
Conclusions and implications 
The thesis sought to provide and assess suitability of an alternative food supplement for 
AL. We have shown that if milk is not available, it is possible to recommend fortification 
of locally available carbohydrate rich staple food with little fat (maize porridge plus 
vegetable oil) to achieve similar LUM absorption. This is a strategy towards improving 
appropriate use of AL in resource limited user populations. 
 
A simple, fast and sensitive analytical method for simultaneous quantification of LUM and 
its metabolite, DBL in human plasma was developed based on liquid chromatography-
tandem mass spectrometry. The method was successfully applied for plasma LUM and 
DBL determination in children < 5 years of age with uncomplicated malaria, up to 28 days 
after a standard 3-day treatment with AL. 
Current AL regimen employs fixed body weight-based dosing. We have demonstrated that 
LUM CL/F is partly a function of age and BMI while VC/F of LUM is partly a function of 
body weight. In this under five year old children population, BMI, a composite variable of 
weight and height, was more important than weight and stunting alone in explaining the 
variability in LUM CL/F. The CL/F of LUM was slightly higher in those less than 2 years 
old when compared with those older than 2 years of age and it decreased with age as 
subject age increased from two to five years old. Additionally, the CL/F of LUM increased 
with decreasing BMI.  
Our findings provide a structural pharmacokinetic framework for a rational approach to re-
evaluating AL dosage guidelines for children less than 5 years of age. The finding further 
suggests that age specific AL dose schemes with BMI adjustments could be considered for 
improved AL dosage regimen in under five year old children. 
Recommendations for future work  
 To explore PK-PD relationship (of LUM and DBL PK, parasitological response and 
patient characteristics) to address the question of rational dosage regimens for LUM in 
children under 5 years of age.  
 To assess the impact of malnutrition on LUM exposure and malaria treatment 
outcomes among under five year old children during AL treatment.  
o To further evaluate the influence of BMI on LUM exposure and treatment 
outcomes. 
o To assess whether BMI can be used as a practical basis for rational AL dose 
modification among children. 
 To further explore the effectiveness of AL in a larger trial, when given with either oil 
fortified food as a practical alternative instead of milk under real life situations among 
< 5 year old children with uncomplicated malaria. 
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